MIND MEDICINE MINDMED INC (MNMD) Stock Price, Quote, News and Overview
NASDAQ:MNMD - Nasdaq - CA60255C8850 - Common Stock - Currency: USD
MNMD Quote, Performance and Key Statistics
6.49
-0.06 (-0.92%)
The current stock price of MNMD is 6.49 USD. In the past month the price decreased by -10.61%. In the past year, price decreased by -8.33%.
MNMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.65 | 738.79B | ||
| JNJ | JOHNSON & JOHNSON | 15.2 | 367.53B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.7 | 306.68B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.56 | 239.01B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 15.88 | 216.66B | ||
| MRK | MERCK & CO. INC. | 10.16 | 198.77B | ||
| PFE | PFIZER INC | 7.55 | 137.81B | ||
| SNY | SANOFI-ADR | 10.57 | 117.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.31 | 94.20B | ||
| GSK | GSK PLC-SPON ADR | 8.51 | 77.82B | ||
| ZTS | ZOETIS INC | 25.91 | 69.43B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 64.42 | 48.29B |
Related stock screener links
About MNMD
Company Profile
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2015-05-04. The firm is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, its lead product candidates. Its lead product candidate, MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder and major depressive disorder. Its second lead product candidate, MM402, also referred to as R(-)-MDMA, is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Company Info
MIND MEDICINE MINDMED INC
One World Trade Center, Suite 8500
New York City NEW YORK US
Employees: 74
Phone: 12122206633
MIND MEDICINE MINDMED INC / MNMD FAQ
What is the stock price of MIND MEDICINE MINDMED INC today?
The current stock price of MNMD is 6.49 USD. The price decreased by -0.92% in the last trading session.
What is the ticker symbol for MIND MEDICINE MINDMED INC stock?
The exchange symbol of MIND MEDICINE MINDMED INC is MNMD and it is listed on the Nasdaq exchange.
On which exchange is MNMD stock listed?
MNMD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MIND MEDICINE MINDMED INC stock?
16 analysts have analysed MNMD and the average price target is 25.76 USD. This implies a price increase of 296.84% is expected in the next year compared to the current price of 6.49. Check the MIND MEDICINE MINDMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MIND MEDICINE MINDMED INC worth?
MIND MEDICINE MINDMED INC (MNMD) has a market capitalization of 490.32M USD. This makes MNMD a Small Cap stock.
How many employees does MIND MEDICINE MINDMED INC have?
MIND MEDICINE MINDMED INC (MNMD) currently has 74 employees.
What are the support and resistance levels for MIND MEDICINE MINDMED INC (MNMD) stock?
MIND MEDICINE MINDMED INC (MNMD) has a support level at 6.54 and a resistance level at 6.82. Check the full technical report for a detailed analysis of MNMD support and resistance levels.
Should I buy MIND MEDICINE MINDMED INC (MNMD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MNMD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MNMD, evaluating the profitability, health, valuation and growth aspects
- MIND MEDICINE MINDMED INC (MNMD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MIND MEDICINE MINDMED INC (MNMD) Sales and EPS estimates to see what analysts future expectations are.
- MIND MEDICINE MINDMED INC (MNMD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MIND MEDICINE MINDMED INC (MNMD) Insider and Institutional Ownership to learn about the owners and their transactions.
- MIND MEDICINE MINDMED INC (MNMD) Stock Chart to make your own analysis
- MIND MEDICINE MINDMED INC (MNMD) Latest news and press-releases to stay up to date.
Does MIND MEDICINE MINDMED INC (MNMD) stock pay dividends?
MNMD does not pay a dividend.
When does MIND MEDICINE MINDMED INC (MNMD) report earnings?
MIND MEDICINE MINDMED INC (MNMD) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of MIND MEDICINE MINDMED INC (MNMD)?
MIND MEDICINE MINDMED INC (MNMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).
What is the Short Interest ratio of MIND MEDICINE MINDMED INC (MNMD) stock?
The outstanding short interest for MIND MEDICINE MINDMED INC (MNMD) is 15.78% of its float. Check the ownership tab for more information on the MNMD short interest.
MNMD Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MNMD. When comparing the yearly performance of all stocks, MNMD turns out to be only a medium performer in the overall market: it outperformed 45.54% of all stocks.
MNMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MNMD. MNMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MNMD Financial Highlights
Over the last trailing twelve months MNMD reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 58.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.19% | ||
| ROE | -34.84% | ||
| Debt/Equity | 0.1 |
MNMD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to MNMD. The Buy consensus is the average rating of analysts ratings from 16 analysts.